Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
27 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
AmVac AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'AmVac AG - Product Pipeline Review - 2014', provides an overview of the AmVac AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of AmVac AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of AmVac AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of AmVac AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the AmVac AG's pipeline products Reasons to buy - Evaluate AmVac AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of AmVac AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the AmVac AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of AmVac AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of AmVac AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of AmVac AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 AmVac AG Snapshot 5 AmVac AG Overview 5 Key Information 5 Key Facts 5 AmVac AG - Research and Development Overview 6 Key Therapeutic Areas 6 AmVac AG - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 AmVac AG - Pipeline Products Glance 10 AmVac AG - Late Stage Pipeline Products 10 Phase III Products/Combination Treatment Modalities 10 AmVac AG - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 AmVac AG - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 AmVac AG - Drug Profiles 13 AMV-100 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 AMV-110 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 AMV-401 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 AMV-411 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 AMV-601 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 AMV-602 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 AMV-603 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 AMV-611 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 AmVac AG - Pipeline Analysis 21 AmVac AG - Pipeline Products by Route of Administration 21 AmVac AG - Pipeline Products by Molecule Type 22 AmVac AG - Recent Pipeline Updates 23 AmVac AG - Dormant Projects 24 AmVac AG - Locations And Subsidiaries 25 Head Office 25 Appendix 26 Methodology 26 Coverage 26 Secondary Research 26 Primary Research 26 Expert Panel Validation 26 Contact Us 27 Disclaimer 27
List of Tables AmVac AG, Key Information 5 AmVac AG, Key Facts 5 AmVac AG - Pipeline by Indication, 2014 7 AmVac AG - Pipeline by Stage of Development, 2014 8 AmVac AG - Monotherapy Products in Pipeline, 2014 9 AmVac AG - Phase III, 2014 10 AmVac AG - Phase II, 2014 11 AmVac AG - Preclinical, 2014 12 AmVac AG - Pipeline by Route of Administration, 2014 21 AmVac AG - Pipeline by Molecule Type, 2014 22 AmVac AG - Recent Pipeline Updates, 2014 23 AmVac AG - Dormant Developmental Projects,2014 24
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.